发明名称 |
Gain-of-function ADAMTS13 variants resistant to auto antibody inhibition and methods of use thereof |
摘要 |
Compositions and methods for the treatment of thrombotic thrombocytopenic purpura are disclosed. |
申请公布号 |
US9546360(B2) |
申请公布日期 |
2017.01.17 |
申请号 |
US201414312041 |
申请日期 |
2014.06.23 |
申请人 |
The Children's Hospital of Philadelphia |
发明人 |
Zheng X. Long |
分类号 |
A61K38/16;A61K38/00;C12P21/06;C12N1/22;C12N9/50;C12N9/64;A61K38/48;A61K48/00 |
主分类号 |
A61K38/16 |
代理机构 |
Dann, Dorfman, Hererll & Skillman |
代理人 |
Rigaut Kathleen D.;Dann, Dorfman, Hererll & Skillman |
主权项 |
1. An isolated, recombinantly produced gain-of-function a disintegrin and metalloprotease with thromboppondin type 1 repeats-13 (ADAMTS13) human variant protein comprising at least one amino acid change in a spacer domain of the full-length ADAMTS13 comprising amino acids 1-2050, said variant having increased proteolytic activity of multimeric von Willebrand factor (VWF) and exhibiting resistance to anti-ADAMTS13 autoantibody inhibition relative to wild typc the human ADAMTS13 lacking said at least one amino acid change, wherein said variant is selected from the group consisting of:
i) an M4 variant, wherein an arginine at position 660 is replaced with a lysine, a phenylalanine at position 592 is replaced with a tyrosine, an arginine at position 568 is replaced with a lysine and an arginine at position 661 is replaced with a phenylalanine; and ii) an M5 variant, wherein an arginine at position 660 is replaced with a lysine, a phenylalanine at position 592 is replaced with a tyrosine, an arginine at position 568 is replaced with a lysine, an arginine at position 661 is replaced with a phenylalanine and a tyrosine at position 665 is replaced with a phenylalanine. |
地址 |
Philadelphia PA US |